PIAZZA ROCCO GIOVANNI

Ducci, G., Ciufolini, G., Campioni, G., Pasquale, V., Gigliotti, G., Ponzetto, S., et al. (2026). FGFR3 oncogenic activation drives oxidative metabolic reprogramming in bladder cancer: a systems metabolomics approach. COMMUNICATIONS BIOLOGY [10.1038/s42003-026-10356-z]. Detail

Barone, C., Quattrini, G., Muratore, A., Anselmi, G., Park, Y., Mehmood, N., et al. (2026). Fetal-restricted hematopoietic progenitors arise from hemogenic endothelium in vitelline and umbilical arteries. NATURE CARDIOVASCULAR RESEARCH [10.1038/s44161-026-00793-8]. Detail

Crippa, V., Cordani, N., Villa, A., Malighetti, F., Villa, M., Sala, L., et al. (2025). Author Correction: Integrative analysis of KEAP1/NFE2L2 alterations across 3600+ tumors reveals an NRF2 expression signature as a prognostic biomarker in cancer (npj Precision Oncology, (2025), 9, 1, (291), 10.1038/s41698-025-01088-0) [Altro] [10.1038/s41698-025-01114-1]. Detail

Villa, M., Cazzaniga, G., Bolognesi, M., Malighetti, F., Crippa, V., Aroldi, A., et al. (2025). Integrative multi-omics analysis enables a comprehensive characterization of prostate cancer and unveils metastasis-associated candidate biomarkers. HELIYON, 11(12 (July 2025)) [10.1016/j.heliyon.2025.e43533]. Detail

Crippa, V., Cordani, N., Villa, A., Malighetti, F., Villa, M., Sala, L., et al. (2025). Integrative analysis of KEAP1/NFE2L2 alterations across 3600+ tumors reveals an NRF2 expression signature as a prognostic biomarker in cancer. NPJ PRECISION ONCOLOGY, 9(1) [10.1038/s41698-025-01088-0]. Detail